MX344580B - Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. - Google Patents
Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.Info
- Publication number
- MX344580B MX344580B MX2013014805A MX2013014805A MX344580B MX 344580 B MX344580 B MX 344580B MX 2013014805 A MX2013014805 A MX 2013014805A MX 2013014805 A MX2013014805 A MX 2013014805A MX 344580 B MX344580 B MX 344580B
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- treatment
- relates
- ruxolitinib
- panobinostat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una combinación que comprende: (a) Compuesto A ((R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol -1-il)-3-ciclopentilpropanonitrilo) de la Fórmula (A): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo; y (b) Compuesto B (N-hidroxi-3-[4-[[[2-(2-metil-1 H-indol-3-il)-etil]-am ino]metil]fenil]-2E-2-propenamida) de la Fórmula (B): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo; para uso simultáneo, concurrente, separado o secuencial, especialmente para uso en el tratamiento de enfermedades proliferativas. La invención también se refiere a composiciones farmacéuticas que comprenden tal combinación y a un método para tratar enfermedades proliferativas, en un mamífero, particularmente un humano, con tal combinación. La presente invención adicionalmente también se refiere a un empaque o producto comercial que comprende tal combinación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496750P | 2011-06-14 | 2011-06-14 | |
| US201161568717P | 2011-12-09 | 2011-12-09 | |
| PCT/US2012/042174 WO2012174061A1 (en) | 2011-06-14 | 2012-06-13 | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014805A MX2013014805A (es) | 2014-01-24 |
| MX344580B true MX344580B (es) | 2016-12-20 |
Family
ID=47357438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014805A MX344580B (es) | 2011-06-14 | 2012-06-13 | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20140113919A1 (es) |
| EP (1) | EP2720696B1 (es) |
| JP (1) | JP6200884B2 (es) |
| KR (1) | KR20140056212A (es) |
| CN (1) | CN103608012A (es) |
| AU (2) | AU2012271814A1 (es) |
| BR (1) | BR112013032125A2 (es) |
| CA (1) | CA2844407A1 (es) |
| CL (1) | CL2013003577A1 (es) |
| CO (1) | CO6821954A2 (es) |
| EA (1) | EA027654B1 (es) |
| ES (1) | ES2595407T3 (es) |
| GT (1) | GT201300308A (es) |
| IL (1) | IL229766A (es) |
| MX (1) | MX344580B (es) |
| NZ (1) | NZ618367A (es) |
| PE (1) | PE20140604A1 (es) |
| PH (1) | PH12013502523A1 (es) |
| SG (1) | SG195141A1 (es) |
| WO (1) | WO2012174061A1 (es) |
| ZA (1) | ZA201308815B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| EP2734205B1 (en) | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| US11007194B2 (en) | 2011-11-11 | 2021-05-18 | Array Biopharma Inc. | Method of treating a proliferative disease |
| WO2013078264A1 (en) | 2011-11-23 | 2013-05-30 | Novartis Ag | Pharmaceutical formulations |
| RU2015121367A (ru) * | 2012-11-08 | 2017-01-10 | Новартис Аг | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний |
| JP6479818B2 (ja) * | 2013-05-10 | 2019-03-06 | シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード | 骨髄増殖性新生物の治療に適した化合物 |
| WO2015184087A2 (en) | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| EP3183252B1 (en) * | 2014-08-21 | 2021-05-12 | ratiopharm GmbH | Oxalate salt of ruxolitinib |
| WO2016047592A1 (ja) * | 2014-09-22 | 2016-03-31 | 国立研究開発法人科学技術振興機構 | 抗インフルエンザウイルス剤、及び抗インフルエンザウイルス剤のスクリーニング方法 |
| CZ2014773A3 (cs) * | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| EP3611506B1 (en) | 2015-04-20 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| PL3298021T3 (pl) | 2015-05-18 | 2019-11-29 | Tolero Pharmaceuticals Inc | Proleki alvocidibu o zwiększonej biodostępności |
| WO2016196991A1 (en) * | 2015-06-04 | 2016-12-08 | Children's Hospital Medical Center | Therapeutic targeting of myeloproliferative neoplasms by dusp1 inhibition |
| WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
| WO2017196261A1 (en) * | 2016-05-11 | 2017-11-16 | National University Of Singapore | Jak and hdac dual-inhibitor compounds |
| WO2017209766A1 (en) * | 2016-06-03 | 2017-12-07 | Q3 Medical Devices Limited | Stent |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CA3095580A1 (en) * | 2018-04-13 | 2019-10-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| EA202190751A1 (ru) * | 2018-09-25 | 2021-06-28 | Импакт Биомедисинс, Инк. | Способы лечения миелопролиферативных расстройств |
| US20220072002A1 (en) * | 2018-12-24 | 2022-03-10 | Chia Tai Tianqing Pharmaceuticalgroup Co., Ltd. | Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound |
| AU2020221247B2 (en) | 2019-02-12 | 2024-12-12 | Sumitomo Pharma America, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| BR112022009710A2 (pt) * | 2019-11-22 | 2022-08-09 | Incyte Corp | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 |
| WO2021154976A1 (en) * | 2020-01-28 | 2021-08-05 | Secura Bio, Inc. | Methods of treating brain cancer with panobinostat |
| CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| EP2491923A3 (en) * | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| HUE029236T2 (en) * | 2007-06-13 | 2017-02-28 | Incyte Holdings Corp | (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor |
| WO2012112847A1 (en) * | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
-
2012
- 2012-06-13 CA CA2844407A patent/CA2844407A1/en not_active Abandoned
- 2012-06-13 NZ NZ618367A patent/NZ618367A/en not_active IP Right Cessation
- 2012-06-13 PE PE2013002816A patent/PE20140604A1/es not_active Application Discontinuation
- 2012-06-13 EA EA201490016A patent/EA027654B1/ru not_active IP Right Cessation
- 2012-06-13 EP EP12730099.4A patent/EP2720696B1/en active Active
- 2012-06-13 AU AU2012271814A patent/AU2012271814A1/en not_active Abandoned
- 2012-06-13 ES ES12730099.4T patent/ES2595407T3/es active Active
- 2012-06-13 US US14/123,855 patent/US20140113919A1/en not_active Abandoned
- 2012-06-13 JP JP2014515936A patent/JP6200884B2/ja not_active Expired - Fee Related
- 2012-06-13 PH PH1/2013/502523A patent/PH12013502523A1/en unknown
- 2012-06-13 CN CN201280029599.0A patent/CN103608012A/zh active Pending
- 2012-06-13 WO PCT/US2012/042174 patent/WO2012174061A1/en not_active Ceased
- 2012-06-13 KR KR1020147000599A patent/KR20140056212A/ko not_active Ceased
- 2012-06-13 MX MX2013014805A patent/MX344580B/es active IP Right Grant
- 2012-06-13 SG SG2013087002A patent/SG195141A1/en unknown
- 2012-06-13 BR BR112013032125A patent/BR112013032125A2/pt not_active IP Right Cessation
-
2013
- 2013-11-22 ZA ZA2013/08815A patent/ZA201308815B/en unknown
- 2013-12-02 IL IL229766A patent/IL229766A/en not_active IP Right Cessation
- 2013-12-11 CO CO13290159A patent/CO6821954A2/es not_active Application Discontinuation
- 2013-12-12 GT GT201300308A patent/GT201300308A/es unknown
- 2013-12-13 CL CL2013003577A patent/CL2013003577A1/es unknown
-
2017
- 2017-06-29 AU AU2017204469A patent/AU2017204469A1/en not_active Abandoned
- 2017-10-06 US US15/726,541 patent/US20180085371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2844407A1 (en) | 2012-12-20 |
| PE20140604A1 (es) | 2014-05-13 |
| CO6821954A2 (es) | 2013-12-31 |
| ES2595407T3 (es) | 2016-12-29 |
| AU2012271814A1 (en) | 2013-12-12 |
| EA027654B1 (ru) | 2017-08-31 |
| WO2012174061A1 (en) | 2012-12-20 |
| BR112013032125A2 (pt) | 2016-12-13 |
| CN103608012A (zh) | 2014-02-26 |
| EA201490016A1 (ru) | 2014-04-30 |
| ZA201308815B (en) | 2014-07-30 |
| KR20140056212A (ko) | 2014-05-09 |
| US20140113919A1 (en) | 2014-04-24 |
| PH12013502523A1 (en) | 2019-10-11 |
| EP2720696B1 (en) | 2016-05-25 |
| AU2017204469A1 (en) | 2017-07-20 |
| MX2013014805A (es) | 2014-01-24 |
| EP2720696A1 (en) | 2014-04-23 |
| IL229766A (en) | 2017-10-31 |
| IL229766A0 (en) | 2014-01-30 |
| US20180085371A1 (en) | 2018-03-29 |
| HK1193045A1 (zh) | 2014-09-12 |
| CL2013003577A1 (es) | 2014-08-01 |
| SG195141A1 (en) | 2013-12-30 |
| NZ618367A (en) | 2016-01-29 |
| JP2014517039A (ja) | 2014-07-17 |
| JP6200884B2 (ja) | 2017-09-20 |
| GT201300308A (es) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502523A1 (en) | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| MX2010006799A (es) | Benzofuropirimidinonas como inhibidores de la proteina cinasa. | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| TN2009000344A1 (en) | Combinations of therapeutic agents for treating cancer | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| EA201591662A1 (ru) | Липиды и липидные композиции для доставки активных агентов | |
| MX2009009590A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
| SG194756A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
| UA95281C2 (en) | Trisubstituted 1,2,4-triazoles | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| IN2015DN00528A (es) | ||
| MY172729A (en) | Pharmaceutical formulations | |
| MX2014006004A (es) | Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| MX2016004936A (es) | Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |